OA11722A - Methods and compositions for restoring conformational stability of a protein of the p53 family. - Google Patents

Methods and compositions for restoring conformational stability of a protein of the p53 family. Download PDF

Info

Publication number
OA11722A
OA11722A OA1200100136A OA1200100136A OA11722A OA 11722 A OA11722 A OA 11722A OA 1200100136 A OA1200100136 A OA 1200100136A OA 1200100136 A OA1200100136 A OA 1200100136A OA 11722 A OA11722 A OA 11722A
Authority
OA
OAPI
Prior art keywords
alkyl
hydroxy
protein
aryl
phenyl
Prior art date
Application number
OA1200100136A
Other languages
English (en)
Inventor
Heather Anne Coffey
Richard Damian Connell
Barbara Ann Foster
Farzan Rastinejad
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11722A publication Critical patent/OA11722A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
OA1200100136A 1998-12-02 1999-12-01 Methods and compositions for restoring conformational stability of a protein of the p53 family. OA11722A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11054298P 1998-12-02 1998-12-02

Publications (1)

Publication Number Publication Date
OA11722A true OA11722A (en) 2005-01-25

Family

ID=22333594

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100136A OA11722A (en) 1998-12-02 1999-12-01 Methods and compositions for restoring conformational stability of a protein of the p53 family.

Country Status (25)

Country Link
US (1) US20020048271A1 (sh)
EP (1) EP1137418A2 (sh)
JP (2) JP2002531396A (sh)
KR (1) KR20010086073A (sh)
CN (1) CN1329493A (sh)
AP (1) AP2001002153A0 (sh)
AU (1) AU1290700A (sh)
BG (1) BG105599A (sh)
BR (1) BR9915940A (sh)
CA (1) CA2350597A1 (sh)
EA (1) EA003326B1 (sh)
EE (1) EE200100302A (sh)
HK (1) HK1041644A1 (sh)
HR (1) HRP20010414A2 (sh)
HU (1) HUP0201215A2 (sh)
ID (1) ID29061A (sh)
IL (1) IL143094A0 (sh)
IS (1) IS5943A (sh)
NO (1) NO20012737L (sh)
OA (1) OA11722A (sh)
PL (1) PL348310A1 (sh)
TR (1) TR200101549T2 (sh)
WO (1) WO2000032175A2 (sh)
YU (1) YU35401A (sh)
ZA (1) ZA200104210B (sh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2003000853A2 (en) * 2001-06-20 2003-01-03 Caprion Pharmaceuticals Inc. Protein aggregation assays and uses thereof
CA2454768A1 (en) * 2001-08-10 2003-02-20 Medical Research Council Molecule
US20050221324A1 (en) * 2002-05-06 2005-10-06 Fox Michael H Genotoxicity analysis
AU2003258662A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
DE60307049T2 (de) * 2003-04-25 2007-02-08 Neuro3D Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS
US6970791B1 (en) * 2003-05-23 2005-11-29 Verachem, Llc Tailored user interfaces for molecular modeling
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) * 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
US20070099950A1 (en) * 2003-11-21 2007-05-03 Jongwon Lim Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
US20080039409A1 (en) * 2003-12-24 2008-02-14 Locomogene, Inc. Method of Suppressing Cancer
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
AU2005251735A1 (en) * 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
US20070021433A1 (en) * 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US7790474B1 (en) 2005-07-15 2010-09-07 Schering Corporation p53 modulators
MX2008000744A (es) * 2005-07-15 2008-03-10 Schering Corp Derivados de quinazolina utiles en el tratamiento del cancer.
JP5162574B2 (ja) 2006-03-22 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｄｍ２及びｐ５３間の相互作用のインヒビターとしての環式アルキルアミン誘導体
CA2644643C (en) 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
NZ546477A (en) * 2006-04-07 2009-04-30 Auckland Uniservices Ltd 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
WO2008008358A2 (en) 2006-07-10 2008-01-17 Columbia University Anti-cocaine compositions and treatment
WO2008155441A1 (en) * 2007-06-20 2008-12-24 Marikki Laiho Activators and therapeutic applications thereof
DK2170373T3 (da) * 2007-07-10 2014-10-13 Univ Columbia Termostabilisering af proteiner
WO2009019274A1 (en) 2007-08-06 2009-02-12 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between mdm2 and p53
ES2639752T3 (es) 2009-02-04 2017-10-30 Janssen Pharmaceutica N.V. Inhibidores de la interacción entre MDM2 y p53
WO2011127406A2 (en) * 2010-04-09 2011-10-13 The Brigham And Women's Hospital, Inc. Acridines as inhibitors of haspin and dyrk kinases
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
EP2758403B1 (en) 2011-09-21 2016-04-27 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN102660257B (zh) * 2012-05-22 2013-11-27 南京邮电大学 吩噻嗪基喹唑啉类荧光离子探针及其应用
SI3201234T1 (sl) 2014-09-30 2019-03-29 Diadem S.R.L. Protitelo, ki veže linearni epitop humanega P53 in njegove diagnostične aplikacije
CN105399670B (zh) * 2015-12-02 2018-04-17 广西中医药大学 一种苯并(c)吖啶酰胺基硫脲衍生物及其制备方法和用途
CN105418501B (zh) * 2015-12-02 2018-04-17 广西中医药大学 7‑对甲氧苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途
CN105399671B (zh) * 2015-12-02 2018-04-17 广西中医药大学 7‑对甲苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途
US11230578B2 (en) 2016-02-04 2022-01-25 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53
CA3215564A1 (en) * 2016-02-19 2017-08-24 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
CN109694358B (zh) * 2019-01-23 2022-02-08 广西师范大学 2-对硝苯乙烯基-4-取代氨基喹唑啉衍生物及其制备方法和应用
WO2021061643A1 (en) * 2019-09-23 2021-04-01 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
US20210405056A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. Methods for detecting mutant p53 function
US11938124B2 (en) 2020-06-24 2024-03-26 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer
GB202111035D0 (en) * 2021-07-30 2021-09-15 Vestlandets Innovasjonsselskap As Therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
ATE327330T1 (de) * 1994-03-08 2006-06-15 Sloan Kettering Inst Cancer Rekombinante humanisierte antikörper gegen fb5
ATE354638T1 (de) * 1994-12-13 2007-03-15 Human Genome Sciences Inc Menschlicher gewebsinhibitor von metalloproteinase-4
US6107332A (en) * 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
EP0959877A4 (en) * 1996-04-10 2000-08-23 Univ California CORRECTION OF GENETIC DEFECTS USING CHEMICAL CAPS
US6270954B1 (en) * 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
DE19624154A1 (de) * 1996-06-18 1998-01-08 Hoechst Ag Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung
US5932613A (en) * 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
KR20000035920A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 헤테로고리성 메탈로프로테아제 저해제
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6284923B1 (en) * 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
US6387903B1 (en) * 1997-08-27 2002-05-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
FI105554B (fi) * 1998-05-13 2000-09-15 Galilaeus Oy Geenimuunnelluista Streptomyces galilaeus-kannoista saatavat hybridiantrasykliinit
US6395749B1 (en) * 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
DE69921151T2 (de) * 1998-08-12 2005-06-02 Daiichi Pure Chemicals Co. Ltd. Fluorszierende marker
SE9900941D0 (sv) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
WO2000066125A1 (en) * 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
AU7847800A (en) * 1999-10-15 2001-04-30 Mayo Foundation For Medical Education And Research Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
US6372785B1 (en) * 2000-05-04 2002-04-16 Keith Chan, President Globoasia, Llc Synthesis of 1,8-dichloro-anthracene analogues and pharmaceutical compositions based thereon
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6395771B1 (en) * 2000-05-31 2002-05-28 Dabur Research Foundation Paclitaxel derivatives for the treatment of cancer
US6391916B1 (en) * 2000-07-21 2002-05-21 The Hong Kong University Of Science And Technology Enediyne derivatives

Also Published As

Publication number Publication date
ID29061A (id) 2001-07-26
JP2002531396A (ja) 2002-09-24
HUP0201215A2 (en) 2002-08-28
EE200100302A (et) 2002-08-15
AU1290700A (en) 2000-06-19
KR20010086073A (ko) 2001-09-07
TR200101549T2 (tr) 2001-11-21
HRP20010414A2 (en) 2002-06-30
PL348310A1 (en) 2002-05-20
EP1137418A2 (en) 2001-10-04
HK1041644A1 (zh) 2002-07-19
WO2000032175A2 (en) 2000-06-08
NO20012737D0 (no) 2001-06-01
YU35401A (sh) 2005-07-19
AP2001002153A0 (en) 2001-06-30
WO2000032175A3 (en) 2000-08-03
IS5943A (is) 2001-05-15
BR9915940A (pt) 2001-09-11
NO20012737L (no) 2001-07-09
CN1329493A (zh) 2002-01-02
CA2350597A1 (en) 2000-06-08
EA200100502A1 (ru) 2001-12-24
IL143094A0 (en) 2002-04-21
US20020048271A1 (en) 2002-04-25
ZA200104210B (en) 2003-02-24
EA003326B1 (ru) 2003-04-24
BG105599A (en) 2002-02-28
JP2006166920A (ja) 2006-06-29

Similar Documents

Publication Publication Date Title
OA11722A (en) Methods and compositions for restoring conformational stability of a protein of the p53 family.
Peraro et al. Diversity-oriented stapling yields intrinsically cell-penetrant inducers of autophagy
Liu et al. Discovery of orally bioavailable chromone derivatives as potent and selective BRD4 inhibitors: scaffold hopping, optimization, and pharmacological evaluation
CN106164071B (zh) 作为治疗剂的人雄激素受体dna-结合结构域(dbd)化合物及其使用方法
AU781272B2 (en) Compositions and methods for modulating apoptosis in cells over-expressing Bcl-2 family member proteins
US20050239873A1 (en) 2 Methoxy antimycin a derivatives and methods of use
US7241804B1 (en) Compositions and methods for modulating apoptosis in cells over-expressing Bcl-2 family member proteins
KR20020019126A (ko) 트리펩티드를 함유하는 약학 조성물
JP2008515385A (ja) Ｉａｐタンパク質とのｈｓｐ９０タンパク質−タンパク質相互作用を阻害する化合物
Gambini et al. Structure-based design of novel EphA2 agonistic agents with nanomolar affinity in vitro and in cell
US20230293499A1 (en) Compositions and methods for inhibiting carp-1 binding to nemo
KR20060127141A (ko) Ｈｍ74의 조절제로서의 푸로세미드 유도체 및 염증 치료를위한 이의 용도
Gu et al. Potent antiviral effect of protoporphyrin IX and verteporfin on SARS-CoV-2 infection
Zhang et al. Medicinal chemistry strategies for the development of inhibitors disrupting β-catenin’s interactions with its nuclear partners
KR20080106404A (ko) Ｐｄｚ 상호작용의 소형 분자 억제제
US9440980B2 (en) Remedy for diabetes
EP1480042A2 (en) Method of screening compounds interacting with proteins of the p53 family
EP1854509A2 (en) Methods and compositions for restoring conformational stability of a protein of the p53 family
US20240190930A1 (en) Nemo coiled coil mimics and methods of using same
MXPA01005557A (en) METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
Foo New approaches to targeting transcription factors in hormone-dependent cancers
Zhou et al. Development of Novel Indole-Based Covalent Inhibitors of TEAD as Potential Antiliver Cancer Agents
CN116135873A (zh) 试剂盒、靶向p53的多肽及其在制备用于治疗癌症的药物中的应用
Xu Part I. A small-molecule library strategy for disruption of protein-protein interactions. Part II. Antibody-catalyzed anaerobic destruction of methamphetamine: A new direction in immunopharmacotherapy. Part III. Design and synthesis of reactive immunization haptens
JP2006111592A (ja) 血管新生阻害剤